



Erich Schlick appointed to Chairman of the Board of Directors of biotech company Phialogics

Basel - May 15, 2023

Phialogics AG is delighted to announce the appointment of Prof. Dr. Erich Schlick as Chairman of its Board of Directors.

Erich has been supporting Phialogics already in 2022 as a consultant and has recently been elected as board member and chairman of the company.

He is a Medical Doctor and Professor of Immunopharmacology. Prior to joining Phialogics, he was a General Partner at Wellington Partners, a former Deputy Head of 3i Healthcare Worldwide and a former member of the BASF Pharma Board with responsibility for research and development of Humira.

Andreas Ernst, CEO of Phialogics, says: “We are very much looking forward to working with Erich and benefiting from his broad experience and knowledge. Erich’s appointment will help strengthen the relationships with the biotech ecosystem and investment community. Phialogics will also benefit from his extensive, successful, and proven experience in drug development. After receiving pre-seed financing from BaseLaunch and HTGF, having Erich with us is a strategic move for our company to bring new solutions to patients with immunological diseases who need better treatment options.”

Erich Schlick says: “I am excited to join the startup company Phialogics AG as chairman of its board of directors because the company’s technology platform and its lead product offer new avenues for the treatment of serious immune disorders. I look forward to working with the founders of Phialogics and its team to further advance the technology and move the lead product into formal development.”

About Phialogics

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space.

The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics.

<https://www.phialogics.com>

Phialogics Media contact:

Pascal Oromi: p.oromi@phialogics.com